Eli Lilly catch ups convenience edge with launch of Mounjaro KwikPen in India, ETPharma

New Delhi: US pharma giant Eli Lilly has announced the launch of its Tirzepatide brand prefilled pen Mounjaro KwikPen narrowing the conceive gap with its rival Wegovy.

MounjaroKwikPen is a multi-dose, single-patient-use prefilled pen which contains four fixed doses, administered once weekly.

The pen will be available in six dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, and will allow healthcare professionals to personalize treatment plans to better suit individual patient needs, the company said in its release.

“We believe this innovation will support healthcare professionals in delivering more personalized and effective treatment plans, helping to improve outcomes and advance the quality of care for people living with these serious diseases,” said Winselow Tucker, President and General Manager, Lilly.

Earlier the drug was marketed in vials and was launched under two dosage strengths—2.5 mg priced at Rs 3,500 per vial and 5 mg vial priced at Rs 4,375 per vial.

Meanwhile, its rival brand Wegovy was already launched in a prefilled pen format by drugmaker Novo Nordisk.

The newly launched prefilled pen is priced the same as before: Rs 14,000 for the 2.5 mg (covering the monthly schedule) and Rs 17,500 for the 5 mg variant.

Lilly has also expanded its portfolio with the launch of prefilled pens in 7.5 mg, 10 mg, 12.5 mg, and 15 mg strengths, priced at Rs 22,500 for the first two strengths and Rs 27,500 for the latter two.

Mounjaro, a GIP/GLP-1 dual agonist is a blockbuster therapy indicated for the treatment of type-2 diabetes.

Currently the drug is marketed by Eli Lilly and is based on the same active ingredient ‘Tirzepatide’ used for the company weight-loss brand Zepbound.

In India, according to PharmaTrac data the brand has recorded total sales of 157 thousand vials—both 2.5 mg and 5 mg—translating into a total turnover of Rs 98 crore in four months of its launch, led by “aggressive marketing.”

• Published On Aug 13, 2025 at 02:05 PM IST

Join the community of 2M+ industry professionals.

Subscribe to Newsletter to get latest insights & analysis in your inbox.

Get updates on your preferred social platform

Follow us for the latest news, insider access to events and more.

_{Images are for reference only.Images and contents gathered automatic from google or 3rd party sources.All rights on the images and contents are with their legal original owners.}